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Abstract
Background Coronary bypass artery grafting (CABG) has a higher procedural risk of stroke than percutaneous coronary 
intervention (PCI), but may offer better long-term survival. The optimal revascularization strategy for patients with prior 
cerebrovascular disease (CEVD) remains unclear.
Methods and results The SYNTAXES study assessed the vital status out to 10 year of patients with three-vessel disease and/
or left main coronary artery disease enrolled in the SYNTAX trial. The relative efficacy of PCI vs. CABG in terms of 10 year 
all-cause death was assessed according to prior CEVD. The primary endpoint was 10 year all-cause death. The status of 
prior CEVD was available in 1791 (99.5%) patients, of whom 253 patients had prior CEVD. Patients with prior CEVD were 
older and had more comorbidities (medically treated diabetes, insulin-dependent diabetes, metabolic syndrome, peripheral 
vascular disease, chronic obstructive pulmonary disease, impaired renal function, and congestive heart failure), compared 
with those without prior CEVD. Prior CEVD was an independent predictor of 10 year all-cause death (adjusted HR: 1.35; 
95% CI: 1.04–1.73; p = 0.021). Patients with prior CEVD had a significantly higher risk of 10 year all-cause death (41.1 vs. 
24.1%; HR: 1.92; 95% CI: 1.54–2.40; p < 0.001). The risk of 10 year all-cause death was similar between patients receiving 
PCI or CABG irrespective of the presence of prior CEVD  (p-interaction = 0.624).
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Conclusion Prior CEVD was associated with a significantly increased risk of 10 year all-cause death which was similar in 
patients treated with PCI or CABG. These results do not support preferential referral for PCI rather than CABG in patients 
with prior CEVD.
Trial registration: SYNTAX: ClinicalTrials.gov reference: NCT00114972. SYNTAX Extended Survival: ClinicalTrials.
gov reference: NCT03417050.
Graphic abstract
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Abbreviations
CABG  Coronary artery bypass grafting
CAD  Coronary artery disease
CEVD  Cerebrovascular disease
LMCAD  Left main coronary artery disease
PCI  Percutaneous coronary intervention
RCTs  Randomized controlled trials
TIA  Transient ischemic attack
3VD  Three-vessel disease
Introduction
The relationship between cerebrovascular disease (CEVD) 
and coronary artery disease (CAD) has been extensively 
investigated with numerous studies confirming that CEVD 
shares common vascular risk factors with CAD [1, 2]. 
Moreover, the presence of CEVD is associated with worse 
clinical outcomes after coronary revascularization, and has 
been reported to be an independent risk factor of long-term 
mortality in patients with CAD [3–5].
Randomized controlled trials (RCTs) have consist-
ently shown that coronary revascularization by coronary 
artery bypass grafting (CABG) as opposed to percutaneous 
coronary intervention (PCI) is associated with an increased 
risk of stroke [6–8]. In contemporary clinical practice, 
patients with prior CEVD are often referred for PCI instead 
of CABG due to concerns from patients and cardiovascu-
lar physicians of a higher rate of perioperative stroke and 
cognitive decline after CABG. Of note, patients with prior 
CEVD are more likely to have more extensive CAD than 
those without CEVD, which can lead to poorer clinical out-
comes after PCI [3–5, 9]. Therefore, determining the optimal 
method of revascularization for patients with prior CEVD 
remains challenging.
To date, there are no data evaluating the impact of 
prior CVED on long-term (up to 10 years) mortality after 
revascularization, especially in patients with de novo 
three-vessel (3VD) and/or left main coronary artery dis-
ease (LMCAD). The SYNTAX Extended Survival (SYN-
TAXES) study established unique 10 year all-cause death 
in 94% all-comers patients with de novo 3VD and/or 
LMCAD who were originally randomized to CABG or 
PCI in the SYNTAX trial [10]. We therefore aim to evalu-
ate the relative benefit of PCI versus CABG in terms of 
all-cause death at 10 years according to prior CEVD in the 
SYNTAXES study.




The SYNTAX study design and the primary and final 
5 year results of the trial have been published previously 
[11–13]. In brief, the trial was a prospective, international, 
multicenter, RCT conducted at 85 centers in Europe and 
the United States between March 2005 and April 2007. 
Based on clinical judgment and the consensus of the Heart 
Team consisting of a cardiothoracic surgeon and an inter-
ventional cardiologist and supported by the study coor-
dinator at each center, all-comers patients with de novo 
3VD and/or LMCAD in whom clinical equipoise in terms 
of revascularization strategy between CABG and PCI was 
assumed, were enrolled and randomized in a 1:1 fashion 
to either CABG (n = 897) or PCI (n = 903) with TAXUS 
Express paclitaxel-drug eluting stents (PES) (Boston Sci-
entific Corporation, Marlborough, MA, USA). The SYN-
TAX trial (NCT00114972) completed patient follow-up up 
to 5 years [13]. The SYNTAXES study (NCT03417050) 
was an investigator-driven initiative that extended follow-
up and aimed to evaluate vital status up to 10 years [10]. 
The extended follow-up was funded by the German Heart 
Research Foundation (GHF; Frankfurt am Main, Ger-
many). Follow-up was performed in accordance with local 
regulations of each participating site and complied with 
the declaration of Helsinki. Informed consent to assess 
vital status up to 10 year of follow-up was waived by the 
medical ethical committee.
Definition of prior CEVD
Prior CEVD was defined as prior stroke, transient ischemic 
attack (TIA), or carotid artery disease (carotid stent, endar-
terectomy, known carotid stenosis or bruit without revas-
cularization, or other), which is consistent with a previous 
report of the EXCEL trial [14]. The presence of prior CEVD 
was assessed in every patient before randomization by the 
investigators and collected on the electronic case report 
form.
Study endpoints
The pre-specified primary endpoint of the SYNTAXES 
study was all-cause death at 10 years. The pre-specified sec-
ondary endpoint was all-cause death at maximum follow-up. 
Vital status was confirmed by electronic healthcare record 
review and national death registry.
Statistical analyses
All the analyses were performed according to intention to 
treat principle. The cumulative incidence of clinical adverse 
events up to 10 years was assessed using the Kaplan–Meier 
method and compared using the log-rank test. Hazard ratio 
(HR) with 95% confidence interval (CI) was assessed by 
a Cox proportional regression model. Multivariate analy-
sis was performed to evaluate whether prior CEVD was 
an independent predictor of all-cause death at 10 year or 
the maximum follow-up. The Cox proportional hazards 
regression model included the following covariates: age, 
gender, body mass index, hypertension, dyslipidemia, dia-
betes mellitus, current smoking, peripheral vascular dis-
ease, Chronic Obstructive Pulmonary Disease  (COPD), 
impaired renal function (defined as a calculated creatinine 
clearance < 60 ml/min using the Cockcroft–Gault equation), 
prior myocardial infarction, the anatomical SYNTAX score 
and randomized strategy (CABG or PCI). Unfortunately, 
the relatively small numbers of the specific components of 
CEVD precluded analysis of the effect of revascularization 
by type of CEVD.
Continuous variables are reported as mean ± standard 
deviations (SD) or median and interquartile range (IQR), and 
were compared using Student’s t tests or Mann–Whitney U 
test, respectively. Categorical variables are reported as per-
centages and numbers and were compared using Chi-square 
or Fisher’s exact test as appropriate. All tests are two-sided 
and a p value of < 0.05 was considered to be statistically sig-
nificant. All analyses were performed using SPSS Statistics, 
version 25 (IBM Corp., Armonk, 281NY, USA).
Results
Study population
In the SYNTAX trial, a total of 1800 patients were ran-
domly assigned to undergo PCI with paclitaxel eluting stents 
(n = 903) or CABG (n = 897). The status of prior CEVD was 
available in 1791 (99.5%) patients who made up the cohort 
for the present analysis. Among them, 253 (14.1%) patients 
had prior CEVD (78 patients had prior stroke, 84 patients 
had prior TIA, and 148 had prior carotid artery disease) 
(Fig. 1). Vital status at 10 year follow-up was complete in 
839 (93%) patients in the PCI group and 841 (94%) patients 
in the CABG group.
Outcomes according to prior CEVD
Baseline characteristics according to prior CEVD are shown 
in Table 1. Patients with prior CEVD were older, had more 
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comorbidities (medically treated diabetes, insulin-dependent 
diabetes, metabolic syndrome, peripheral vascular disease, 
chronic obstructive pulmonary disease, impaired renal func-
tion, and congestive heart failure), and had a higher Euro-
SCORE and Parsonnet SCORE, compared with those with-
out prior CEVD. Patients with prior CEVD had more lesions 
treated compared with those without prior CEVD.
The median duration of follow-up was 11.2 years (IQR: 
7.7–12.1) overall and 11.9 years (IQR: 11.2–12.4) in sur-
vivors. When compared to those without prior CEVD, 
patients with prior CEVD had a significantly higher risk 
of all-cause death at 10 years (41.1 vs. 24.1%; HR: 1.92; 
95% CI: 1.54–2.40; p < 0.001) and at maximum follow-up 
of 12.6 years (53.8 vs. 32.5%; HR: 1.99; 95% CI: 1.62–2.43; 
p < 0.001) (Fig. 2a, Online Fig. S1A, Table 2).
By multivariate analysis, prior CEVD was an independ-
ent predictor of all-cause death at 10 years (adjusted HR: 
1.35; 95% CI: 1.04–1.73; p = 0.021) and at maximum follow-
up of 12.6 years (adjusted HR: 1.45; 95% CI: 1.16–1.82; 
p = 0.001) (Online Tables S1 and S2).
Clinical outcomes according to revascularization 
strategy
Among patients with prior CEVD, 119 and 134 patients 
were randomly assigned to PCI and CABG, respectively. 
Among 1538 patients without prior CEVD, 782 and 756 
patients were randomized to PCI and CABG, respectively 
(Fig. 1).
Baseline clinical and procedural characteristics according 
to prior CEVD and revascularization strategies are shown in 
Table 3. By randomization, baseline clinical and procedural 
characteristics were largely well balanced between PCI and 
CABG in patients with and without prior CEVD.
Compared with those without prior CEVD, the risk of 
10-year all-cause death was higher in patients with prior 
CEVD both in the PCI arm (46.0 vs. 25.9%; HR: 2.06; 95% 
CI: 1.52–2.79; p < 0.001) and in the CABG arm (36.8 vs. 
22.2%; HR: 1.83; 95% CI: 1.32–2.53; p < 0.001) (Fig. 2b, 
c), and these differences remained significant at maximum 
follow-up of 12.6 years for PCI (53.8 vs. 35.7%; HR: 1.93; 
95% CI: 1.45–2.57; p < 0.001) and CABG (53.2 vs. 29.2%; 
HR: 2.09; 95% CI: 1.57–2.77; p < 0.001) (Online Fig. S1b, 
c). However, the risk of all-cause death at 10 years was simi-
lar between PCI and CABG irrespective of the presence of 
prior CEVD (P-interaction = 0.624) (Table 4).
Clinical outcomes according to complexity 
of coronary artery disease (3VD or LMCAD)
The limited number of events precluded a subgroup analysis 
according to SYTNTAX score; we performed the analysis 
according to 3VD or LMCAD. Results demonstrated that 
rates of all-cause death at 10 years and maximum follow-up 
were numerically higher after PCI than after CABG but not 
significantly different in both 3VD and LMCAD patients 
with prior CEVD (Online Fig. S2).
Discussion
The SYNTAXES study is the first study to investigate 10 year 
survival after PCI with drug eluting stents versus CABG 
in patients with de novo3VD and/or LMCAD. The present 
analysis is the first study to evaluate the potential relative 
benefit of PCI versus CABG in terms of all-cause death at 
10 years according to prior CEVD in stable patients with 
complex CAD. The main findings of the present study can be 
summarized as follows: (1) prior CEVD (14.1%) was com-
mon among patients with de novo 3VD and/or LMCAD and 
they had more comorbidities and more extensive CAD com-
pared with those without CEVD; (2) prior CEVD was asso-
ciated with a significantly increased risk of all-cause death 
Fig. 1   Patient flow diagram 
of the present study. CABG 
coronary artery bypass grafting, 
CEVD cerebrovascular disease, 
PCI percutaneous coronary 
intervention, TIA transient 
ischemic attack
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Table 1   Baseline 
characteristics according to 
prior CEVD




 PCI 47.0 (119) 50.8 (782)
 CABG 53.0 (134) 49.2 (756)
 Age (year) 68.2 ± 8.7 64.6 ± 9.8  < 0.001
Sex 0.159
 Male 74.3 (188) 78.3 (1204)
 Female 25.7 (65) 21.7 (334)
Body mass index (kg/m2) 27.9 ± 4.6 28.0 ± 4.7 0.638
Medically treated diabetes 32.4 (82) 23.9 (367) 0.004
 On insulin 15.0 (38) 9.2 (142) 0.005
Metabolic syndrome 43.1 (109) 35.4 (544) 0.041
Hypertension 70.4 (178) 65.7 (1010) 0.144
Dyslipidemia 78.8 (197) 77.8 (1187) 0.720
Current smoker 16.8 (42) 20.8 (319) 0.145
Previous myocardial infarction 35.3 (88) 32.6 (496) 0.392
Previous stroke 31.3 (78) 0 (0)  < 0.001
Previous transient ischemic attack 33.7 (84) 0 (0)  < 0.001
Previous carotid artery disease 58.5 (148) 0 (0)  < 0.001
Peripheral vascular disease 24.5 (62) 7.5 (115)  < 0.001
Chronic obstructive pulmonary disease 14.6 (37) 7.5 (115)  < 0.001
Impaired renal function 32.6 (74) 17.2 (241)  < 0.001
Creatinine clearance (ml/min) 77.0 ± 32.5 87.6 ± 32.6  < 0.001
Left ventricular ejection fraction 57.4 ± 13.1 58.9 ± 13 0.174
Congestive heart failure 7.3 (18) 4.3 (65) 0.036
Clinical presentation  < 0.001
Silent ischemia 22.1 (56) 13.1 (202)
Stable angina 48.6 (123) 58.5 (899)
Unstable angina 29.2 (74) 28.4 (437)
Euro SCORE 5.6 ± 3.0 3.5 ± 2.5  < 0.001
Parsonnet SCORE 11.0 ± 7.6 8.0 ± 6.7  < 0.001
Disease extent 0.489
 3VD 58.9 (149) 61.2 (941)
 LMCAD 41.1 (104) 38.8 (597)
Disease extent 0.509
 LMCAD only 3.6 (9) 5.2 (80)
 LMCAD + 1VD 8.3 (21) 7.6 (117)
 LMCAD + 2VD 11.9 (30) 12.2 (187)
 LMCAD + 3VD 17.4 (44) 13.9 (213)
 2VD 1.2 (3) 2.1 (33)
 3VD 57.7 (146) 59 (907)
Anatomical SYNTAX score 29.9 ± 11.7 28.6 ± 11.3 0.097
Number of lesions 4.6 ± 1.8 4.3 ± 1.8 0.048
Any total occlusion 23.7 (60) 23.1 (353) 0.843
Any bifurcation 73.9 (187) 72.6 (1107) 0.662
Number of stents 4.7 ± 2.2 4.6 ± 2.3 0.639
Total stent length per patient 85.5 ± 45.5 85.7 ± 48.4 0.969
Off pump CABG 16.4 (21) 14.9 (109) 0.668
LIMA use 85.9 (110) 86.0 (629) 0.974
Number of total conduits 2.8 ± 0.7 2.8 ± 0.7 0.495
 Number of arterial conduits 1.4 ± 0.7 1.4 ± 0.7 0.497
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at 10 years; (3) the relative effects of PCI versus CABG on 
10 year all-cause death were similar, irrespective of whether 
patients had prior CEVD or not.
Patients with CAD often have prior CEVD, which itself 
is associated with a higher prevalence of CAD [1, 2, 15]. 
Numerous studies have demonstrated that CAD patients 
with prior CEVD are more likely to have a diffuse, complex 
and higher disease burden and multiple comorbidities [3–5]. 
Patients with prior CEVD therefore represent a high risk 
population and are often excluded from coronary revascu-
larization trials. However, with advances in PCI and CABG 
techniques, more and more patients with prior CEVD are 
undergoing revascularization in contemporary practice. 
In our study, 14.1% of patients who underwent coronary 
revascularization had a prior history of CEVD, which is 
comparable to the 12.3% observed in the EXCEL (Evalu-
ation of XIENCE Versus Coronary Artery Bypass Surgery 
for Effectiveness of Left Main Revascularization) trial [14].
Prior CEVD has been shown to be associated with worse 
clinical outcomes after coronary revascularization [3–5, 9, 
16]. Indeed, we found that prior CEVD was associated with 
a significantly increased risk of all-cause death at 10 years 
in both the PCI and CABG arms. These poorer outcomes 
may most likely be due to the advanced age and presence 
of a greater number of comorbidities (peripheral vascular 
disease, chronic obstructive pulmonary disease, impaired 
renal function) and cardiac risk factors (diabetes, metabolic 
syndrome) in the CEVD patient cohort (Table 1), some 
of which were also found to be independent predictors of 
10 year all-cause mortality. These observations were further 
validated by the fact that history of prior CEVD remained 
an independent predictor of all-cause death at 10 years and 
at maximum follow-up (12.6 years)even after multivari-
ate adjustment for important clinical confounders (Online 
Tables S1 and S2).
The optimal revascularization strategy for complex CAD 
patients with prior CEVD remains unclear. Stroke is one 
of the most devastating complications after coronary revas-
cularization, leading to a higher risk of mortality and per-
manent disability [17]. Most previous studies demonstrated 
that CABG carried a higher rate of stroke, especially in the 
periprocedural period [6–8, 18]. Hence, in clinical practice, 
patients with prior CEVD are often referred for PCI instead 
of CABG. However, recent studies have shown that CABG 
only increased the risk of perioperative stroke, while the 
rate of long-term stroke was comparable between PCI and 
CABG [7, 18–21]. Moreover, as aforementioned, patients 
with prior CEVD, who have complex and diffuse CAD and 
multiple comorbidities, and who undergo PCI may expe-
rience increased rates of recurrent cerebrovascular events, 
myocardial infarction, and death9, [16, 22]. It is important 
to balance the risk of stroke, which represents the major 
adverse event of CABG, against the risk of other adverse 
events such as repeat revascularization, myocardial infarc-
tion and death, when determining the optimal revasculariza-
tion modality between CABG and PCI in patients with prior 
CEVD [23, 24]. Hence, whether high-risk patients with prior 
CEVD would benefit from PCI rather than CABG is debat-
able, and there are only limited data supporting this. In addi-
tion, intense pre-operative evaluation of patient risk factors, 
careful assessment of supra-aortic vessels and ascending 
aorta for atherosclerotic disease, use of off-pump “no-touch 
Table 1  (continued) Prior CEVD (n = 253) No prior CEVD 
(n = 1538)
p value
 Number of venous conduits 1.4 ± 0.9 1.4 ± 0.9 0.932
Complete revascularization 58.1 (144) 60.1 (907) 0.543
Fig. 2   Kaplan–Meier curves for the primary endpoint of all-
cause death up to 10  years in patients without (blue) or with prior 
CEVD  (red). a Overall population; b PCI cohort; c CABG cohort. 
CABG coronary artery bypass grafting, CEVD cerebrovascular dis-
ease, PCI percutaneous coronary intervention
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Table 2  Clinical outcomes 
according to prior CEVD
Data are presented as percentage (number of events). MACCE was defined as a composite of all-cause 
death, any stroke, any MI, or any revascularization. MACCE major adverse cardiac and cerebrovascular 
events, MI myocardial infarction
Prior CEVD (n = 253) No prior  
CEVD 
(n = 1538)
HR (95% CI) p value
At 30 days
 MACCE 1.6 (4) 0.6 (9) 1.56 (0.94–2.58) 0.084
 Death, stroke, MI 5.1 (13) 4.1 (63) 1.26 (0.69–2.29) 0.448
 All-cause death 2.4 (6) 1.2 (19) 1.93 (0.77–4.84) 0.159
  Cardiac death 2.4 (6) 1.2 (19) 1.93 (0.77–4.84) 0.159
 Any MI 2.0 (5) 3.3 (50) 0.61 (0.24–1.53) 0.293
 Any stroke 1.2 (3) 0.6 (9) 2.04 (0.55–7.53) 0.285
 Any repeat revascularization 2.8 (7) 2.1 (33) 1.30 (0.58–2.95) 0.522
At 5 years
 MACCE 39.1 (99) 29.9 (460) 1.41 (1.13–1.75) 0.002
 Death, stroke, MI 27.3 (69) 16.7 (257) 1.73 (1.33–2.26)  < 0.001
 All-cause death 19.4 (49) 11.0 (169) 1.88 (1.37–2.58)  < 0.001
  Cardiac death 9.9 (25) 6.3 (97) 1.66 (1.07–2.57) 0.025
 Any MI 7.9 (20) 6.2 (96) 1.32 (0.81–2.13) 0.262
 Any stroke 4.3 (11) 2.6 (40) 1.74 (0.89–3.39) 0.103
 Any repeat revascularization 18.2 (46) 18.6 (286) 1.05 (0.77–1.43) 0.770
At 10 years
 All-cause death 41.1 (100) 24.1 (357) 1.92 (1.54–2.40)  < 0.001
At maximum follow-up
 All-cause death 53.8 (121) 32.5 (442) 1.99 (1.62–2.43)  < 0.001
aorta” surgery, monitoring of cerebral oximetry for early 
detection and treatment of cerebral hypoxia, and prevention 
and treatment of post-operative atrial fibrillation may reduce 
the risk of perioperative stroke in CABG-treated patients 
[25, 26].
Recently, Jamie et  al. investigated whether high-risk 
patients with LMCAD and prior CEVD preferentially ben-
efit from revascularization by PCI compared with CABG 
in the EXCEL trial. They demonstrated that patients with 
LMCAD and prior CEVD, when compared with those with-
out CEVD, had higher rates of stroke and reduced event-free 
survival after revascularization, irrespective of the mode of 
the revascularization. Overall, patients with prior CEVD had 
higher rates of stroke at 30 days (2.2 vs. 0.8%; p = 0.05) and 
3 years (6.4 vs. 2.2%; p = 0.0003) and higher 3 year rates of 
the primary endpoint of all-cause death, stroke, or myocar-
dial infarction (25.0 vs. 13.6%; p < 0.0001) [14]. Notably, 
no data pertaining to the impact of previous CEVD on very 
long-term (up to 10 years) mortality after revascularization 
in patients with 3VD and/or LMCAD are available. Not sur-
prisingly, in our present analyses, we demonstrated that prior 
CEVD was associated with a significantly increased risk of 
all-cause death at 10 years, with no significant interaction 
between prior CEVD and revascularization strategy for the 
relative risk of all-cause death at 10 years. These findings 
do not support the strategy that patients with prior CEVD 
should be preferentially referred for PCI rather than CABG. 
Instead, the heart team [27] should assess the risk/benefit 
ratio of CABG versus PCI, by considering the periproce-
dural surgical risk, anatomical complexity, possibility for 
complete revascularization, potential procedural complica-
tions, benefits of each treatment strategy that emerge over 
time (beyond the periprocedural period), and patient pref-
erences[28] when selecting the optimal revascularization 
strategy for 3VD and/or LMCVD patients with prior CEVD.
Limitations
Our findings should be interpreted in light of the following 
limitations. First, the present study is a post hoc analysis 
and should be considered as hypothesis-generating only 
[29]. In the multivariate analysis, a variety of available 
confounders have been adjusted for, even though, some 
may exist that may have not been identified. Second, the 
prior CEVD was site reported and the screening for CEVD 
was left to the discretion of each physician, which could 
lead to an underestimation of the rate of CEVD. Third, 
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Table 3  Baseline characteristics according to prior CEVD and revascularization strategies
Prior CEVD No prior CEVD
PCI (n = 119) CABG (n = 134) p value PCI (n = 782) CABG (n = 756) p value
Age (year) 67.4 ± 8.6 68.8 ± 8.8 0.211 64.9 ± 9.8 64.2 ± 9.8 0.170
Sex 0.202 0.312
Male 70.6 (84) 77.6 (104) 77.2 (604) 79.4 (600)
Female 29.4 (35) 22.4 (30) 22.8 (178) 20.6 (156)
Body mass index (kg/m2) 28.2 ± 4.8 27.6 ± 4.4 0.343 28.1 ± 4.8 28.0 ± 4.5 0.603
Medically treated diabetes 31.9 (38) 32.8 (44) 0.878 24.6 (192) 23.1 (175) 0.518
Insulin 16.0 (19) 14.2 (19) 0.691 9.0 (70) 9.5 (72) 0.698
Metabolic syndrome 47.9 (57) 38.8 (52) 0.203 35.9 (281) 34.8 (263) 0.304
Hypertension 77.3 (92) 64.2 (86) 0.022 67.5 (528) 63.8 (482) 0.120
Dyslipidemia 78.0 (92) 79.5 (105) 0.760 78.7 (611) 76.8 (576) 0.363
Current smoker 16.0 (19) 17.6 (23) 0.737 18.8 (147) 22.9 (172) 0.049
Previous myocardial infarction 31.6 (37) 38.6 (51) 0.248 32.0 (248) 33.2 (248) 0.643
Previous stroke 29.9 (35) 32.6 (43) 0.651 – –
Previous transient ischemic attack 33.1 (39) 34.4 (45) 0.828 – –
Previous carotid artery disease 61.3 (73) 56 (75) 0.387 – –
Peripheral vascular disease 24.4 (29) 24.6 (33) 0.962 6.8 (53) 8.2 (62) 0.289
Chronic obstructive pulmonary disease 18.5 (22) 11.2 (15) 0.101 6.3 (49) 8.7 (66) 0.066
Impaired renal function 30.4 (34) 34.8 (40) 0.477 18.0 (133) 16.2 (108) 0.377
Creatinine clearance (ml/min) 77.8 ± 32.2 76.2 ± 32.8 0.703 87.9 ± 35.9 87.3 ± 28.5 0.705
Left ventricular ejection fraction (%) 57.5 ± 12.8 57.2 ± 13.4 0.885 59.3 ± 12.9 58.5 ± 13.2 0.357
Congestive heart failure 6.8 (8) 7.8 (10) 0.783 3.6 (28) 5.0 (37) 0.183
Clinical presentation 0.153 0.835
Silent ischemia 16.8 (20) 26.9 (36) 13.6 (106) 12.7 (96)
Stable angina 51.3 (61) 46.3 (62) 57.8 (452) 59.1 (447)
Unstable angina 31.9 (38) 26.9 (36) 28.6 (224) 28.2 (213)
Euro SCORE 5.5 ± 3.1 5.6 ± 3.0 0.731 3.5 ± 2.4 3.5 ± 2.5 0.760
Parsonnet SCORE 10.4 ± 7.6 11.6 ± 7.5 0.217 8.2 ± 6.8 7.8 ± 6.5 0.232
Disease extent 0.430 0.962
3VD 56.3 (67) 61.2 (82) 61.1 (478) 61.2 (463)
LMCAD 43.7 (52) 38.8 (52) 38.9 (304) 38.8 (293)
Disease extent 0.756 0.841
LMCAD only 5.0 (6) 2.2 (3) 4.6 (36) 5.8 (44)
LMCAD + 1VD 7.6 (9) 9.0 (12) 7.4 (58) 7.8 (59)
LMCAD + 2VD 12.6 (15) 11.2 (15) 12.4 (97) 11.9 (90)
LMCAD + 3VD 18.5 (22) 16.4 (22) 14.5 (113) 13.2 (100)
2VD 1.7 (2) 0.7 (1) 1.9 (15) 2.4 (18)
3VD 54.6 (65) 60.4 (81) 59.2 (463) 58.8 (444)
SYNTAX score 29.7 ± 11.3 30.0 ± 12.0 0.851 28.3 ± 11.4 28.9 ± 11.2 0.255
Number of lesions 4.6 ± 1.9 4.5 ± 1.7 0.878 4.3 ± 1.8 4.4 ± 1.8 0.477
Any total occlusion 26.1 (31) 21.6 (29) 0.411 23.8 (185) 22.4 (168) 0.514
Any bifurcation 75.6 (90) 72.4 (97) 0.558 71.8 (557) 73.4 (550) 0.469
Number of stents 4.7 ± 2.2 – – 4.6 ± 2.3 – –
Total stent length per patient 86.3 ± 45.4 – – 86.3 ± 48.4 – –
Off pump CABG – 16.5 (21) 0.656 – 14.9 (107) 0.651
LIMA use – 85.8 (109) 0.685 – 86.0 (620) 0.716
Number of total conduits – 2.8 ± 0.7 – – 2.8 ± 0.7 –
Number of arterial conduits – 1.4 ± 0.7 – – 1.4 ± 0.7 –
Number of venous conduits – 1.4 ± 0.9 – – 1.4 ± 0.9 –
Complete revascularization 56.3 (67) 59.7 (77) 0.589 56.8 (440) 63.6 (467) 0.007
Data are presented as mean ± standard deviation or percentage (number). CABG coronary artery bypass grafting, CAD coronary artery disease; 
LIMA left internal mammary artery, PCI percutaneous coronary intervention
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analysis, some less severe CEVD was not included. We 
only evaluated the impact of the major CEVD on long-
term all-cause death, which was consistent with most 
previous studies, and the major CEVD may more clini-
cal relevant with the long-term outcomes [14]. Finally, 
the SYNTAX trial was conducted between 2005 and 2007 
with use of the first-generation drug eluting stents that 
were then available for treatment with PCI, which may 
the number of patients with prior CEVD was relatively 
small (n = 253) and the present subgroup analysis may, 
thereby, be underpowered [29]. Therefore, further stud-
ies with large sample sizes are warranted to compare the 
relative treatment benefit of PCI or CABG at extended 
long-term follow-up. In addition, lacking follow-up stroke 
data and the functional neurological outcomes was another 
major limitation of the SYNTAXES study. In our current 
Table 4  Clinical outcomes according to revascularization strategies and prior CEVD
Data are presented as percentage (number of events). MACCE was defined as a composite of all-cause death, any stroke, any MI, or any revascu-
larization. MACCE major adverse cardiac and cerebrovascular events MI myocardial infarction
Prior CEVD No prior CEVD
PCI (n = 119) CABG 
(n = 134)
HR (95% CI) p value PCI (n = 782) CABG 
(n = 756)
HR (95% CI) p value p value for 
interaction
At 30 days
 MACCE 9.2 (11) 6.0 (8) 1.57 (0.63–
3.91)






5.9 (7) 4.5 (6) 1.31 (0.44–
3.91)





3.4 (4) 1.5 (2) 2.26 (0.41–
12.32)





3.4 (4) 1.5 (2) 2.26 (0.41–
12.32)
0.347 1.9 (15) 0.5 (4) 3.61 (1.20–
10.88)
0.022 0.647
 Any MI 2.5 (3) 1.5 (2) 1.69 (0.28–
10.12)
0.565 4.0 (31) 2.5 (19) 1.58 (0.89–
2.79)
0.118 0.937






3.4 (4) 2.2 (3) 1.52 (0.34–
6.80)




 MACCE 48.7 (58) 30.6 (41) 1.77 (1.19–
2.64)
0.005 34.9 (273) 24.7 (187) 1.43 (1.18–
1.72)




31.1 (37) 23.9 (32) 1.33 (0.83–
2.13)





21.0 (25) 17.9 (24) 1.17 (0.67–
2.05)





12.6 (15) 7.5 (10) 1.69 (0.76–
3.76)
0.200 8.1 (63) 4.5 (34) 1.73 (1.14–
2.63)
0.010 0.954
 Any MI 13.4 (16) 3.0 (4) 4.60 (1.54–
13.77)
0.006 8.6 (67) 3.8 (29) 2.20 (1.42–
3.40)
 < 0.001 0.219
 Any stroke 3.4 (4) 5.2 (7) 0.63 (0.18–
2.15)






27.7 (33) 9.7 (13) 3.13 (1.65–
5.95)
 < 0.001 24.2 (189) 12.8 (97) 1.93 (1.51–
2.47)




46.0 (53) 36.8 (47) 1.33 (0.90–
1.97)






53.8 (58) 53.2 (63) 1.13 (0.79–
1.62)
0.502 35.7 (244) 29.2 (198) 1.23 (1.02–
1.48)
0.030 0.668
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limit generalizability of our findings to contemporary clin-
ical practice [30]. Nevertheless, the SYNTAXES study, 
which achieved a relatively high follow-up rate (94%), is 
the first one to provide randomized data on the 10 year 
vital status of patients included in the trial [10].
Conclusions
Presence of prior CEVD in patients with 3VD and/or 
LMCVD planned for a revascularization procedure repre-
sents a high-risk patient group with complex and diffuse 
CAD and multiple comorbidities. A history of CEVD was 
associated with a significantly increased risk of all-cause 
death at 10 years following PCI or CABG. The risk of all-
cause death at 10 years in patients having PCI or CABG 
was not significantly different according to CEVD status. 
The current findings from the SYNTAXES study do not 
support preferential referral for PCI rather than CABG in 
this population on the basis of a history of prior CEVD. 
Instead, decision making needs to include assessment of 
both short- and long-terms risks while discussing strate-
gies amongst care providers and with patients.
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